Pfizer gets FDA nod for second Remicade biosimilar
The Food and Drug Administration recently approved Pfizer’s Ixifi (infliximab-qbtx), the company’s second approved biosimilar of Janssen’s Remicade. The biosimilar was approved for all of Remicade’s indications, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and plaque psoriasis, among others.
The approval follows the April 2016 launch of its first Remicade biosimilar Inflectra. According to reports, Pfizer has said it has no plans to launch Ixifi in the United States.
Outside the United States, Pfizer markets Inflectra, Retacrit (epoetin zeta) and Nivestim (filgrastim). It said that its biosimilars pipeline includes 13 distinct biosimilar molecules in various stages of development.